Immutep completes patient enrolment for EFTISARC-NEO Phase 2 trial
Clinical-stage Australian biotechnology company Immutep (ASX:IMM) has completed enrolment in the investigator-initiated EFTISARC-NEO trial. EFTISARC-NEO is evaluating Immutep’s investigative LAG-3 immunotherapy eftilagimod alpha (efti) in combination with …